M Asaduzzaman1, A Nadeem1, N Arizmendi1, C Davidson1, H L Nichols2, M Abel1, L I Ionescu3, L Puttagunta4, B Thebaud3, J Gordon5, K DeFea2, M D Hollenberg6, H Vliagoftis1. 1. Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, AB, Canada. 2. Division of Biomedical Sciences and Cell, Molecular and Developmental Biology, University of California, Riverside, CA, USA. 3. Department of Physiology, Women and Children Health Research Institute, University of Alberta, Edmonton, AB, Canada. 4. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. 5. Immunology Research Group, University of Saskatchewan, Saskatoon, SK, Canada. 6. Department of Pharmacology and Therapeutics, University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND: Proteinase-activated receptor 2 (PAR2 ) is a G protein-coupled receptor activated by trypsin-like serine proteinases. PAR2 activation has been associated with inflammation including allergic airway inflammation. We have also shown that PAR2 activation in the airways leads to allergic sensitization. The exact contribution of PAR2 in the development of eosinophilic inflammation and airway hyperresponsiveness (AHR) in sensitized individuals is not clear. OBJECTIVE: To investigate whether functional inhibition of PAR2 during allergen challenge of allergic mice would inhibit allergen-induced AHR and inflammation in mouse models of asthma. METHODS: Mice were sensitized and challenged with ovalbumin (OVA) or cockroach extract (CE). To investigate the role of PAR2 in the development of AHR and airway inflammation, we administered blocking anti-PAR2 antibodies, or a cell permeable peptide inhibitor of PAR2 signalling, pepducin, i.n. before allergen challenges and then assessed AHR and airway inflammation. RESULTS: Administration of anti-PAR2 antibodies significantly inhibited OVA- and CE-induced AHR and airway inflammation. In particular, two anti-PAR2 antibodies, the monoclonal SAM-11 and polyclonal B5, inhibited AHR, airway eosinophilia, the increase of cytokines in the lung tissue and antigen-specific T cell proliferation, but had no effect on antigen-specific IgG and IgE levels. Pepducin was also effective in inhibiting AHR and airway inflammation in an OVA model of allergic airway inflammation. CONCLUSIONS AND CLINICAL RELEVANCE: Functional blockade of PAR2 in the airways during allergen challenge improves allergen-induced AHR and inflammation in mice. Therefore, topical PAR2 blockade in the airways, through anti-PAR2 antibodies or molecules that interrupt PAR2 signalling, has the potential to be used as a therapeutic option in allergic asthma.
BACKGROUND:Proteinase-activated receptor 2 (PAR2 ) is a G protein-coupled receptor activated by trypsin-like serine proteinases. PAR2 activation has been associated with inflammation including allergic airway inflammation. We have also shown that PAR2 activation in the airways leads to allergic sensitization. The exact contribution of PAR2 in the development of eosinophilic inflammation and airway hyperresponsiveness (AHR) in sensitized individuals is not clear. OBJECTIVE: To investigate whether functional inhibition of PAR2 during allergen challenge of allergicmice would inhibit allergen-induced AHR and inflammation in mouse models of asthma. METHODS:Mice were sensitized and challenged with ovalbumin (OVA) or cockroach extract (CE). To investigate the role of PAR2 in the development of AHR and airway inflammation, we administered blocking anti-PAR2 antibodies, or a cell permeable peptide inhibitor of PAR2 signalling, pepducin, i.n. before allergen challenges and then assessed AHR and airway inflammation. RESULTS: Administration of anti-PAR2 antibodies significantly inhibited OVA- and CE-induced AHR and airway inflammation. In particular, two anti-PAR2 antibodies, the monoclonal SAM-11 and polyclonal B5, inhibited AHR, airway eosinophilia, the increase of cytokines in the lung tissue and antigen-specific T cell proliferation, but had no effect on antigen-specific IgG and IgE levels. Pepducin was also effective in inhibiting AHR and airway inflammation in an OVA model of allergic airway inflammation. CONCLUSIONS AND CLINICAL RELEVANCE: Functional blockade of PAR2 in the airways during allergen challenge improves allergen-induced AHR and inflammation in mice. Therefore, topical PAR2 blockade in the airways, through anti-PAR2 antibodies or molecules that interrupt PAR2 signalling, has the potential to be used as a therapeutic option in allergic asthma.
Authors: Abigail C Burr; Jalene V Velazquez; Arzu Ulu; Rohan Kamath; Sang Yong Kim; Amanpreet K Bilg; Aileen Najera; Iman Sultan; Jon K Botthoff; Emma Aronson; Meera G Nair; Tara M Nordgren Journal: J Inflamm Res Date: 2021-08-21
Authors: Michael C Yee; Heddie L Nichols; Danny Polley; Mahmoud Saifeddine; Kasturi Pal; Kyu Lee; Emma H Wilson; Michael O Daines; Morley D Hollenberg; Scott Boitano; Kathryn A DeFea Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-10-18 Impact factor: 5.464
Authors: Ariana Corrêa Florencio; Robson S de Almeida; Fernanda M Arantes-Costa; Beatriz M Saraiva-Romanholo; Adriana F Duran; Sérgio D Sasaki; Mílton A Martins; Fernanda D T Q S Lopes; Iolanda F L C Tibério; Edna A Leick Journal: Sci Rep Date: 2019-09-02 Impact factor: 4.379
Authors: Randall C Gunther; Vanthana Bharathi; Stephen D Miles; Lauryn R Tumey; Clare M Schmedes; Kohei Tatsumi; Meagan D Bridges; David Martinez; Stephanie A Montgomery; Melinda A Beck; Eric Camerer; Nigel Mackman; Silvio Antoniak Journal: Front Immunol Date: 2021-12-01 Impact factor: 7.561